Skip to Main Content

Advertisement

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 3, Issue 13
July 9 2019
Issue Cover

Table of Contents

STIMULUS REPORT

Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia
Clinical Trials & Observations
Amy K. Keating,Nathan Gossai,Christine L. Phillips,Kelly Maloney,Kristen Campbell,Andrew Doan,Deepa Bhojwani,Michael J. Burke,Michael R. Verneris
View Articletitled, Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia

REVIEW ARTICLE

Blood disease–causing and –suppressing transcriptional enhancers: general principles and GATA2 mechanisms
Emery H. Bresnick,Kirby D. Johnson
View Articletitled, Blood disease–causing and –suppressing transcriptional enhancers: general principles and <em>GATA2</em> mechanisms

CLINICAL TRIALS AND OBSERVATIONS

Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia
Clinical Trials & Observations
Harry P. Erba,Pamela S. Becker,Paul J. Shami,Michael R. Grunwald,Donna L. Flesher,Min Zhu,Erik Rasmussen,Haby A. Henary,Abraham A. Anderson,Eunice S. Wang
View Articletitled, Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia
Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI
Clinical Trials & Observations
Arnon Nagler,Myriam Labopin,Bhagirathbhai Dholaria,Riitta Niittyvuopio,Johan Maertens,Xavier Poiré,Jan Cornelissen,Péter Reményi,Jean Henri Bourhis,Yves Beguin,Ram Malladi,Tessa Kerre,Wilfried Schroyens,Bipin N. Savani,Mohamad Mohty
View Articletitled, Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI
Supplemental data
Risk for malignancies of infectious etiology among adult survivors of specific non-Hodgkin lymphoma subtypes
Clinical Trials & Observations
Megan M. Herr,Sara J. Schonfeld,Graça M. Dores,Eric A. Engels,Margaret A. Tucker,Rochelle E. Curtis,Lindsay M. Morton
View Articletitled, Risk for malignancies of infectious etiology among adult survivors of specific non-Hodgkin lymphoma subtypes
Supplemental data
Transient and chronic childhood immune thrombocytopenia are distinctly affected by Fc-γ receptor polymorphisms
Clinical Trials & Observations
David E. Schmidt,Katja M. J. Heitink-Pollé,Annemieke G. Laarhoven,Marrie C. A. Bruin,Barbera Veldhuisen,Sietse Q. Nagelkerke,Taco W. Kuijpers,Leendert Porcelijn,C. Ellen van der Schoot,Gestur Vidarsson,Masja de Haas
View Articletitled, Transient and chronic childhood immune thrombocytopenia are distinctly affected by Fc-γ receptor polymorphisms
Supplemental data
Low-dose radiation (4 Gy) with/without concurrent chemotherapy is highly effective for relapsed, refractory mantle cell lymphoma
Clinical Trials & Observations
Matthew S. Ning,Chelsea C. Pinnix,Bhavana V. Chapman,Jillian R. Gunther,Sarah A. Milgrom,Joseph D. Khoury,Preetesh Jain,Wendy Y. Chen,Onyeka N. Oriabure,Maria R. Badillo,L. Michael Wang,Bouthaina S. Dabaja
View Articletitled, Low-dose radiation (4 Gy) with/without concurrent chemotherapy is highly effective for relapsed, refractory mantle cell lymphoma

GENE THERAPY

Long‐term safety and activity of NY-ESO‐1 SPEAR T cells after autologous stem cell transplant for myeloma
Clinical Trials & Observations
Edward A. Stadtmauer,Thomas H. Faitg,Daniel E. Lowther,Ashraf Z. Badros,Karen Chagin,Karen Dengel,Malini Iyengar,Luca Melchiori,Jean-Marc Navenot,Elliot Norry,Trupti Trivedi,Ruoxi Wang,Gwendolyn K. Binder,Rafael Amado,Aaron P. Rapoport
View Articletitled, Long‐term safety and activity of NY-ESO‐1 SPEAR T cells after autologous stem cell transplant for myeloma
Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia
Clinical Trials & Observations
Sarah Cooley,Fiona He,Veronika Bachanova,Gregory M. Vercellotti,Todd E. DeFor,Julie M. Curtsinger,Paul Robertson,Bartosz Grzywacz,Kevin C. Conlon,Thomas A. Waldmann,David H. McKenna,Bruce R. Blazar,Daniel J. Weisdorf,Jeffrey S. Miller
View Articletitled, First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia
Supplemental data

LYMPHOID NEOPLASIA

Impact of acquired del(17p) in multiple myeloma
Clinical Trials & Observations
Arjun Lakshman,Utkarsh Painuly,S. Vincent Rajkumar,Rhett P. Ketterling,Prashant Kapoor,Patricia T. Greipp,Angela Dispenzieri,Morie A. Gertz,Francis K. Buadi,Martha Q. Lacy,David Dingli,Amie L. Fonder,Suzanne R. Hayman,Miriam A. Hobbs,Wilson I. Gonsalves,Yi Lisa Hwa,Nelson Leung,Ronald S. Go,Yi Lin,Taxiarchis V. Kourelis,Rahma Warsame,John A. Lust,Stephen J. Russell,Steven R. Zeldenrust,Robert A. Kyle,Shaji K. Kumar
View Articletitled, Impact of acquired del(17p) in multiple myeloma
Supplemental data
Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemia
Clinical Trials & Observations
Marion Alcantara,Mathieu Simonin,Ludovic Lhermitte,Aurore Touzart,Marie Emilie Dourthe,Mehdi Latiri,Nathalie Grardel,Jean Michel Cayuela,Yves Chalandon,Carlos Graux,Hervé Dombret,Norbert Ifrah,Arnaud Petit,Elizabeth Macintyre,André Baruchel,Nicolas Boissel,Vahid Asnafi
View Articletitled, Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemia
Supplemental data
COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study
Clinical Trials & Observations
Allison Barraclough,Musa Alzahrani,Marianne Schmidt Ettrup,Mark Bishton,Chris van Vliet,Pedro Farinha,Clare Gould,Simone Birch,Laurie H. Sehn,Vishakha Sovani,Mitchell Steven Ward,Bradley Augustson,Jorne Biccler,Joseph M. Connors,David W. Scott,Maher K. Gandhi,Kerry J. Savage,Tarec El-Galaly,Diego Villa,Chan Yoon Cheah
View Articletitled, COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study
Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition
Clinical Trials & Observations
Matthew J. Pianko,Sean M. Devlin,Eric R. Littmann,Aisara Chansakul,Donna Mastey,Meghan Salcedo,Emily Fontana,Lilan Ling,Elizabet Tavitian,John B. Slingerland,Ann E. Slingerland,Annelie Clurman,Antonio L. C. Gomes,Ying Taur,Eric G. Pamer,Jonathan U. Peled,Marcel R. M. van den Brink,Ola Landgren,Alexander M. Lesokhin
View Articletitled, Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition
Supplemental data

MYELOID NEOPLASIA

STAT3β is a tumor suppressor in acute myeloid leukemia
Petra Aigner,Tatsuaki Mizutani,Jaqueline Horvath,Thomas Eder,Stefan Heber,Karin Lind,Valentin Just,Herwig P. Moll,Assa Yeroslaviz,Michael J. M. Fischer,Lukas Kenner,Balázs Győrffy,Heinz Sill,Florian Grebien,Richard Moriggl,Emilio Casanova,Dagmar Stoiber
View Articletitled, STAT3β is a tumor suppressor in acute myeloid leukemia
Supplemental data
All Issues

Advertisement

Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy
Phillips NS, Mulrooney DA, Williams AM, et al. Neurocognitive impairment associated with chronic morbidity in long-term survivors of Hodgkin Lymphoma. Blood Adv. 2023;7(23):7270-7278.
Unleashed monocytic engagement in Sézary syndrome during the combination of anti-CCR4 antibody with type I interferon
A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia
Race and ethnicity reporting and representation in hemophilia clinical trials

Advertisement

Advertisement

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement